[1] 李翀,张希龙,刘皓,等.阻塞性睡眠呼吸暂停低通气综合征患者血浆白细胞介素-18水平与动脉粥样硬化的关系[J].中华结核和呼吸杂,2007,30(12):908-909.
[2] 陆甘,徐卓文,刘剑南,等.阻塞性睡眠呼吸暂停低通气综合征与冠心病的相关性[J].中华结核和呼吸杂志,2007,30(3):178-181.
[3] LU G,XU Z W,ZHANG Y L,et al.Correlation among obstructive sleep apnea syndrome,coronary atherosclerosis and coronary heart disease[J].Chin Med J,2007,120(18):1632-1634.
[4] SILVESFRINI M,RIZZATO B,PLACIDI F,et al.Diomedim carotid artery wall thickness in patients with obstructive sleep apnea syndrome[J].Sfroke,2002,33:1782-1785.
[5] KAYNAK D,GAKSAN B,KAYNAK H,et al.Is there a link between the severity of sleep-disordered breathing and atherosclerotic disease of the carotid aterries?[J].Eur J Neurol,2003,10:487-493.
[6] SALETU M,NOSISKA D,KAPFHAMMER G,et al.Structural and serum surrogates markers of cerebrovascular disease in obstructive dleep apnea.association of mild OSA with early atherosclerosis[J].Neurol,2006,253:746-752.
[7] LATTIMORE J D,WILCOX I,NAKHLA S.Repetitive hypoxia increases lipid loading in human macrophages-a potentially atherogeni effect[J].Atherosclerosis,2005,179(2):255-259.
[8] HAYASHI M,FUJIMOTO K,URUSHIBATA K.Hypoxia-sensitive molecules may modulate the development of atherosclerosis in sleep apnea syndrome[J].Respirology,2006,11(1):24-31.
[9] BREWSTER U C,SETARO J F,PERAZELLA M A.The renin-angiotensin-aldosterone system,cardiorenal effects and implications for renal and cardiovascular disease states[J].Am J Med Sci,2003,326(1):15-24.
[10] PEPIN J L,LEVY P.Pathophysiology of cardiovascular risk in sleep apnea syndrome[J].Rev Neurol(Paris),2002,158(8-9):785-797.
[11] LAVIE L.Obstructive sleep apnea syndrome-an oxidative stress disorder[J].Acta Physiol Scand,2003,177(3):385-390.
[12] VGONTZAS A N,BIXLER E O,CHROUSOS G P.Sleep apnea is a manifestation of the metabolic syndrome[J].Sleep Med Rev,2005,9(3):211-224.
[13] MONTECUCCO F,MACH F.New evidences for C-reactive protein (CRP) deposits in the arterialintima as a cardiovascular risk factor[J].Clin Interv Aging,2008,3(2):341-349.
[14] BLASCHKE F,BRUEMMER D.C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells[J].Circulation,2004,110:579-587.
[15] ANDERSON R A.Tumor necros is factor directly stimulates the production of hepatic apolipoprote in B100-containing VLDL via impairment of hepatic insulin signaling[J].Am J Physiol Gastrointest Liver Physiol,2008,294:1120-1129.
[16] POPA C,NETEA M G,RIEL P L,et al.The role of TNF-alpha in chronic inflammatory conditions,interediarym etabolism,and cardiovascular risk[J].J Lipid Res,2007,48(4):751-762.
[17] RIZVI A A.Inflammation markers as mediators of vasculo-endothelial dysfunction and a therosclerosis in the metabolic syndrome[J].Chin Med J(Engl),2007,120(21):1918-1924.
[18] ZHANG H,PARK Y,WU J,et al.Role of TNF-alpha in vascular dysfunction[J].Clin Sci(Lond),2009,116(3):219-230.
[19] DUNCAN B B,SCHMIDT M I,PANKOW J S,et al.Adiponectin and the development of type 2 diabetes:the atheroclerosis risk in communities study[J].Diabetes,2004,53:2473-2478.
[20] GUZIK T J,MANGALAT D,KORBUT R Adipo cytoines novel link between inflammation and vascular function[J].J Physio l Pharmaco,2006,57(4):505-528.
[21] HARTUNG D,PETROV A,HAIDER N,et al.Radiolabeled monocyte chemotactic protein 1 for the detection of inflammation in experimental atherosclerosis[J].J Nuc Med,2007,48(11):1816-1821.
[22] KOWALSKI J,OKOPIEN B,MADEJ A,et al.Levels of slCAM1,VCAM-1 and MCP-1 in patients with hyperlipoprote inemia a and b[J].Int J Clin Pharmacol Ther,2001,39:48-52.
[23] KOH K K,SON J W,AHN J Y,et al.Vascular effects of simvastatin combined with ramipril in hyper cholesterolemic patients with coronary artery disease,compared with simvastat in alone a randomized,double blind,placebo controlled,cross over study[J] .Atherosclerosis,2004,177:147-153.
[24] ZERNECKE A,BERNHAGEN J,WEBER C.Macrophagem igration inhibitory factor in cardiovascular disease[J].Circulation,2008,117(12):1594-1602.
[25] BURGER K A,GOEBEL H,SEILER R,et al.Expression of macrophagemigration inhibitory factor in different stages of human atherosclerosis[J].Circulation,2002,105:1561-1566.
[26] KORSHUNOV V A,NIKONENKO T A,TKACHUK V A,et al.Interleukin-18 and macrophagem igration inhibitory factor are associated with increased carotidintima media thickening[J].Arterioscler Thromb Vasc Biol,2006,26:295-300.
[27] SCHMEISSER A,MARQUETANT R,ILLMER T,et al.The expression of macrophagem igration inhibitory factor 1alpha (MIF-1alpha) in human atherosclertic plaques is induced by different proatherogenic stimuli and associated with plaqu instability[J].Atherosclerosis,2005,178:83-94.
[28] PAN J H,SUKHOVA G K,YANG J T,et al.Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low density lipoprotein receptor deficientmice[J].Circulation,2004,109:3149-3153.
[29] BERNHAGEN J,KROHN R,LUE H,et al.MIF is a noncognate ligando CXC chemokine receptors in inflammatory and atherogenic cell recruitment[J].Nat Med,2007,13:587-596.
[30] BURGER K,GOBE L,KLEEMANN R,et al Reduction of the aortic inflammatory response in spontaneous atheroscleros is by blockade macrophagm igraion inhibitory factor(MIF)[J].Atherosclerosis,2006,184:28-38.
[31] MORAND E F,LEECH M,BERNHAGEN J.MIF:a new cytokine link between rheumatoid arthritis and atherosclerosis[J].Nat Rev Drug Discov,2006,5(5):399-410.
[32] ZALEWSKI A,MACPHEE C.Role of lipoprote in associated phospholipase A2 in atherosclerosis:biology,epidemiology,and possible therapeutic target[J].Arterioscler Thromb Vasc Biol,2005,25:923-931.
[33] TSIMIKAS S,TSIRONIS L D,TSELEPIS A D.New insights into the role of lipoprotein(a) associated lipoprotein associated phospho lipase A2 in a therosclerosis and cardiovascular disease[J].A rterioscler Thromb Vasc Biol,2007,27(10):2094-2099.
[34] LAVI S,McCONNELL J P,RIHAL C S,et al.Local production of lipoprotein associated phospho lipase A2 and lysophosphatidy lcholine in the coronary circulation:association with early coronary atherosclerosis and endothelial dysfunction in humans[J].Circulation,2007,115:2715-2721.
[35] KOLODGIE F D,BURKE A P,SKORIJA K S,et al.Lipoprote associated phospho lipase protein expression in the natural progression of human coronary atherosclerosis[J].Arterioscle Thromb Vasc Biol,2006,26:2523-2529.
[36] McLAREN J E,RAMJI D P.Interferongamma:a master regulator of atherosclerosis[J].Cytokine Growth Factor Rev,2009,20(2):125-135.《东南大学学报(医学版)》唯一邮箱:bjb@pub.seu.edu.cn |
